Skip to content

Research on the Effect and Mechanism of Aerobic Exercise on PD

Research on the Effect and Mechanism of Aerobic Exercise on Parkinson's

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04651140
Enrollment
30
Registered
2020-12-03
Start date
2020-10-13
Completion date
2021-10-30
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease, Physical Exercise

Keywords

Parkinson's Disease, Physical exercise, Mechanism

Brief summary

This trial is expected to recruit patients with primary Parkinson's disease and give them four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism

Detailed description

This trial is expected to recruit patients with primary Parkinson's disease who are distributed into tremor group and stiff group and give them the same kind of four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism

Interventions

BEHAVIORALaerobic exercise

Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks

Sponsors

The First Hospital of Jilin University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants were diagnosed primary PD according to the 2015 MDS diagnostic criteria * Participants are between 55 and 65 years old

Exclusion criteria

* Severe heart * liver dysfunction * kidney dysfunction * severe cognitive dysfunction * severe anxiety and depression * history of mental illness * history of cerebral infarction or ischemic attack in the past three months * acute myocardial infarction or acute coronary in the past three months * Parkinson's Pulse syndrome * medication history (drugs that improve blood circulation in the brain and increase the excitability of the nervous system)

Design outcomes

Primary

MeasureTime frameDescription
Movement Disorder Society-United Parkinson's Disease Rating Scale (MDS-UPDRS)changes of MDS-UPDRS score from baseline at four weeksto assess the motor and nonmotor function of PD,0-200 scores,the higher scores mean lower function
Montreal Cognitive Assessing(MoCA) scorechanges of MoCA score from baseline at four weeksto assess the cognitive function of PD,0-30 scores,the higher scores mean better function
The Epworth Sleeping Scale(ESS)changes of ESS score from baseline at four weeksto assess the degree of drowsiness, 0-24 scores, the higher scores mean severe drowsiness
Non-Motor Symptom Scale (NMSS)changes of NMSS score from baseline at four weeksto assess the non-motor of PD , 0-120 scores, the higher scores mean severe non-motor damage

Secondary

MeasureTime frameDescription
cerebral blood variation by Head MRIchanges of the cerebral blood from baseline at four weeksto assess the cerebral blood variation by head MRI
cerebral blood flow velocitychanges of the cerebral blood flow velocity from baseline at four weekscerebral blood flow velocity is recorded using transcranial Doppler and a servo-controlled plethysmograph respectively.
the level of arterial blood pressurechanges of the arterial blood pressure from baseline at four weeksarterial blood pressure is recorded using transcranial Doppler and a servo-controlled plethysmograph respectively. Both systolic and diastolic pressures will be assessed during the study period.
the concentration of microRNA in peripheral blood by gene chipchanges of microRNA from baseline at four weeksto test the the concentration of microRNA in peripheral blood

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026